AstraZeneca PLC, Johnson & Johnson Drugs for Schizophrenia May Exacerbate Loss of Brain Tissue, Study Finds

February 8, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Bloomberg -- Anti-psychotic drugs from AstraZeneca Plc and Johnson & Johnson may lead to loss of brain tissue or exacerbate declines in brain volume caused by schizophrenia, a study in the Archives of General Psychiatry found.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Postmarket research

AstraZeneca Johnson & Johnson Family of Companies